FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283313755> ?p ?o ?g. }

• W4283313755 abstract "HomeCirculation: Cardiovascular Quality and OutcomesVol. 15, No. 72022 AHA/ACC Key Data Elements and Definitions for Cardiovascular and Noncardiovascular Complications of COVID-19: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards Free AccessReview ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissionsDownload Articles + Supplements ShareShare onFacebookTwitterLinked InMendeleyRedditDiggEmail Jump toSupplementary MaterialsFree AccessReview ArticlePDF/EPUB2022 AHA/ACC Key Data Elements and Definitions for Cardiovascular and Noncardiovascular Complications of COVID-19: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards Biykem Bozkurt, MD, PhD, FACC, FAHA, Sandeep R. Das, MD, MPH, FACC, FAHA, Daniel Addison, MD, Aakriti Gupta, MD, MS, Hani Jneid, MD, FACC, FAHA, Sadiya S. Khan, MD, MSc, FACC, FAHA, George Augustine Koromia, MD, MMCi, Prathit A. Kulkarni, MD, Kathleen LaPoint, MS, Eldrin F. Lewis, MD, MPH, FACC, FAHA, Erin D. Michos, MD, MHS, FACC, FAHA, Pamela N. Peterson, MD, MSPH, FACC, FAHA, Mohit K. Turagam, MD, MS, FACC, Tracy Y. Wang, MD, MHS, MSc, FACC, FAHA and Clyde W. Yancy, MD, MSc, MACC, FAHA Biykem BozkurtBiykem Bozkurt Search for more papers by this author , Sandeep R. DasSandeep R. Das Search for more papers by this author , Daniel AddisonDaniel Addison Search for more papers by this author , Aakriti GuptaAakriti Gupta Search for more papers by this author , Hani JneidHani Jneid *Task Force liaison. Search for more papers by this author , Sadiya S. KhanSadiya S. Khan Search for more papers by this author , George Augustine KoromiaGeorge Augustine Koromia Search for more papers by this author , Prathit A. KulkarniPrathit A. Kulkarni Search for more papers by this author , Kathleen LaPointKathleen LaPoint †ACC/AHA staff. Search for more papers by this author , Eldrin F. LewisEldrin F. Lewis Search for more papers by this author , Erin D. MichosErin D. Michos Search for more papers by this author , Pamela N. PetersonPamela N. Peterson Search for more papers by this author , Mohit K. TuragamMohit K. Turagam Search for more papers by this author , Tracy Y. WangTracy Y. Wang Search for more papers by this author and Clyde W. YancyClyde W. Yancy Search for more papers by this author Originally published23 Jun 2022https://doi.org/10.1161/HCQ.0000000000000111Circulation: Cardiovascular Quality and Outcomes. 2022;15Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: June 23, 2022: Ahead of Print Table of ContentsTop 10 Take-Home Messages..........e541Preamble..........e5411.Introduction..........e5431.1.Special Considerations..........e5431.2.Abbreviations..........e5432.Methodology..........e5432.1.Writing Committee Composition..........e5432.2.Relationships With Industry and Other Entities..........e5442.3.Review of Literature and Existing Data Definitions..........e5442.4.Development of Terminology Concepts..........e5442.5.Consensus Development..........e5442.6.Relation to Other Standards..........e5442.7.Peer Review, Public Review, and Board Approval..........e5443.Data Elements and Definitions..........e5453.1.Patient Demographics Including Age, Sex, Race, Ethnicity, and Social Determinants of Health..........e5453.2.COVID-19 Diagnosis..........e5453.3.COVID-19 Cardiovascular Complications..........e5453.4.COVID-19 Noncardiovascular Complications..........e5463.5.Symptoms and Signs..........e5463.6.Diagnostic Procedures..........e5463.7.Pharmacological Therapy..........e5473.8.Preventive, Therapeutic, and Supportive Procedures for COVID-19..........e5473.9.End-of-Life Management..........e548References..........e549Appendix 1.Author Relationships With Industry and Other Entities (Relevant)..........e553Appendix 2.Reviewer Relationships With Industry and Other Entities (Comprehensive)..........e553Appendix 3.COVID-19 Diagnosis..........e555Appendix 4.COVID-19 Cardiovascular Complications..........e561Appendix 5.COVID-19 Noncardiovascular Complications..........e574Appendix 6.Symptoms and Signs..........e576Appendix 7.Diagnostic Procedures..........e585Appendix 8.Pharmacological Therapy..........e594Appendix 9.Therapeutic and Supportive Procedures for COVID-19..........e602Appendix 10.End-of-Life Management..........e609Top 10 Take-Home Messages1.This document presents a clinical lexicon comprising data elements related to cardiovascular and noncardiovascular complications of COVID-19 (coronavirus disease-2019). The writing committee considered data elements that are pertinent to the full range of care provided to these patients and intended to be useful for all care venues, including presentations related to acute COVID-19 in the ambulatory as well as the hospital setting.2.Data elements for COVID-19 diagnoses include confirmed, probable, and suspected acute COVID-19 case definitions. Postacute sequelae of SARS-CoV-2 (severe acute respiratory syndrome-coronavirus-2) infection were also included.3.Acute cardiovascular complications related to COVID-19, including acute myocardial injury, heart failure, shock, arrhythmia, thromboembolic complications, and stroke, were defined.4.Data elements related to COVID-19 vaccination status, comorbidities, and preexisting cardiovascular conditions were provided.5.Postacute cardiovascular sequelae of SARS-CoV-2 infection and long-term cardiovascular complications of COVID-19 were defined.6.Data elements for cardiovascular mortality during acute COVID-19 were provided.7.Data elements for noncardiovascular complications were provided to help document severity of illness and other competing diagnoses and complications that may affect cardiovascular outcomes.8.Symptoms and signs related to COVID-19 and cardiovascular complications were listed.9.Data elements for diagnostic and therapeutic strategies for COVID-19 and cardiovascular conditions were provided.10.Advanced therapies, including mechanical ventilation, extracorporeal membrane oxygenation, and end-of-life management strategies, were provided.PreambleThe American College of Cardiology (ACC) and the American Heart Association (AHA) support their members’ goal to improve the prevention and treatment of cardiovascular diseases (CVDs) through professional education, research, the development of guidelines and standards, and by fostering policy that supports optimal patient care and outcomes. The ACC and AHA also recognize the importance of using clinical data standards for patient management, assessment of outcomes, and conduct of research, as well as the importance of defining the processes and outcomes of clinical care, whether in randomized trials, observational studies, registries, or quality improvement initiatives.Clinical data standards aim to identify, define, and standardize data elements relevant to clinical topics in cardiovascular medicine, with the primary goal of assisting data collection and use by providing a corpus of data elements and definitions applicable to various conditions. Broad agreement on common vocabulary and definitions is needed to pool or compare data from the electronic health records (EHRs), clinical registries, administrative datasets, and other databases and to assess whether these data are applicable to clinical practice and research endeavors. Emerging federal standards, such as the US Department of Health & Human Services, Office of the National Coordinator for Health Information Technology, and the US Core Data for Interoperability support efforts to “promote interoperability” and the more effective use of EHR data to improve health care quality. The purpose of clinical data standards is to contribute to the infrastructure necessary to accomplish the ACC’s mission to transform cardiovascular care and improve heart health and the AHA’s mission of being a relentless force for a world of longer and healthier lives for all individuals.The specific goals of clinical data standards are:1.To establish a consistent, interoperable, and universal clinical vocabulary as a foundation for clinical care and research2.To facilitate the exchange of data across systems through harmonized, standardized definitions of key data elements3.To facilitate further development of clinical registries, implementable clinical guidelines, quality and performance improvement programs, outcomes evaluations, public reporting, and clinical research, including the comparison of results within and across these initiatives4.To ensure equity across all endeavors related to clinical data standardsThe key data elements and definitions are a compilation of variables intended to facilitate the consistent, accurate, and reproducible capture of clinical concepts; standardize the terminology used to describe CVDs and procedures; create a data environment conducive to the implementation of clinical guidelines, assessment of patient management and outcomes for quality and performance improvement, and clinical and translational research; and increase opportunities for sharing data across disparate data sources. The ACC/AHA Task Force on Clinical Data Standards (Task Force) selects cardiovascular conditions, procedures, and other topics related to cardiovascular health and medicine that will benefit from the creation of a clinical data standard set. Experts in the subject area are selected to examine and consider existing standards and develop a comprehensive, yet not exhaustive, data standard set. When undertaking a data collection effort, only a subset of the elements contained in a clinical data standard listing may be needed or, conversely, users may want to consider whether it may be necessary to collect and incorporate additional elements. For example, in the setting of a randomized, clinical trial of a new drug, additional information would likely be required regarding study procedures and medical therapies. Alternatively, if a data set is to be used for quality improvement, safety initiatives, or administrative functions, elements such as Current Procedural Terminology (CPT) codes, International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) codes, or outcomes may be added. The intent of the Task Force is to standardize clinical concepts, focusing on the patient and clinical care and not on administrative billing or coding concepts. The clinical concepts selected for development are commonly cardiovascular specific, where a standardized terminology does not already exist. The clinical data standards can, therefore, serve as a guide to develop administrative data sets, and complementary administrative or quality assurance elements can evolve from these core clinical concepts and elements. Thus, rather than forcing the clinical data standards to harmonize with existing administrative codes, such as ICD-10-CM or CPT codes, we envision the administrative codes to follow the lead of the clinical data standards. This approach would allow clinical care to lead standardization of cardiovascular health care terminology.The ACC and AHA recognize that there are other national efforts to establish clinical data standards, and every attempt is made to harmonize newly published standards with existing ones. Writing committees are instructed to consider adopting or adapting existing nationally recognized data standards if the definitions and characteristics are validated, useful, and applicable to the set under development. In addition, the ACC and AHA are committed to continually expanding their portfolio of clinical data standards and will create new standards and update existing ones as needed to maintain their currency and promote harmonization with other standards as health information technology and clinical practice evolve.The Privacy Rule of the Health Insurance Portability and Accountability Act (HIPAA) privacy regulations, which went into effect in April 2003, heightened all health care professionals awareness of our professional commitment to safeguard patients’ privacy. HIPAA privacy regulations specify which information elements are considered “protected health information.” These elements may not be disclosed to third parties (including registries and research studies) without the patient’s permission and meeting all relevant privacy sharing requirements. Protected health information may be included in databases used for health care operations under a data use agreement. Research studies using protected health information must be reviewed by an institutional review board. We have included identifying information in all clinical data standards to facilitate uniform collection of these elements when appropriate. For example, a longitudinal clinic database may contain these elements because access is restricted to the patient’s health care team.In clinical care, health care providers communicate with each other through a common vocabulary. In an analogous manner, the integrity of clinical research depends on firm adherence to prespecified procedures for patient enrollment and follow-up; these procedures are guaranteed through careful attention to definitions enumerated in the study design and case report forms. Harmonizing data elements and definitions across studies facilitates comparisons and enables the conduct of pooled analyses and meta-analyses, thus deepening our understanding of individual study results.The recent development of quality performance measurement initiatives, particularly those for which the comparison of health care professionals and institutions is an implicit or explicit aim, has further raised awareness about the importance of clinical data standards. Indeed, a wide audience, including nonmedical professionals such as payers, regulators, and consumers, may draw conclusions about care and outcomes from these comparisons. To understand and compare care patterns and outcomes, the data elements that characterize them must be clearly defined, consistently used, and properly interpreted.Hani Jneid, MD, FACC, FAHAChair, ACC/AHA Task Force on Clinical Data Standards1. IntroductionThe Task Force has undertaken the task to standardize the lexicon of cardiovascular medicine. This document provides data standards for cardiovascular and other complications related to COVID-19 infection caused by SARS-CoV-2. Our intent is to provide data elements consistent with current practice guidance and to include updated terminology and attributes in compliance with the methodology of the Task Force1 and with current policies of the ACC and AHA regarding harmonization of data across organizations and disciplines. There is increased importance of understanding acute and longitudinal impact of COVID-19 on cardiovascular health. Unfortunately, there has not been clarity or consensus on definitions of cardiovascular conditions related to COVID-19. Different diagnostic terminologies are being used for overlapping conditions such as “myocardial injury,” “myocarditis,” “type II myocardial infarction,” “stress cardiomyopathy,” or “inflammatory cardiomyopathy.”These data standards will help standardize definitions and set the framework to capture and better understand how COVID-19 impacts cardiovascular health. This document is intended for use by researchers, registry developers, and clinicians and is proposed as a framework for ICD-10 code development of COVID-19–related cardiovascular conditions.Specifically, COVID-19 cardiovascular data standards are of great importance to patients, providers, investigators, scientists, administrators, public health officials, policy makers, and payers. The ACC/AHA Writing Committee on Clinical Data Standards for COVID-19 (writing committee) envisions these data elements would be useful in the following broad additional categories:•Communication with patients•Inpatient and outpatient clinical programs•Clinical registries•Basic and translational research programs•Clinical research, particularly where eventual pooled analysis or meta-analysis is anticipated•Public health organizations•Organization and design of electronic medical information initiatives, such as EHRs, pharmacy databases, computerized decision support, and cloud technologies•Public health policy, health insurance coverage, and legislation development•Health system administrators for estimation of necessary resources such as protective personal equipment (PPE), testing, space and staffing needs, isolation, sanitation, or quarantine requirements▪Alternative models of health care such as telemedicine, virtual visits, and point-of-care diagnostic platforms.The data element tables are also included as an Excel file in the Online Data Supplement.1.1. Special ConsiderationsIn this document, data elements were not differentiated for specific encounters, such as for inpatients versus outpatients, dates of encounter, number of encounters, baseline or repeated data elements. Databases can be built and customized according to users’ needs to capture such information. The intent of this writing committee was not to provide recommendations regarding COVID-19 treatment, and the writing committee recommends that readers follow prevailing COVID-19 management guidelines.1.2. AbbreviationsAbbreviationMeaning/PhraseACEangiotensin-converting enzymeACSacute coronary syndromeARBangiotensin receptor blockerCDCCenters for Disease Control and PreventionCOVID-19coronavirus disease-2019CPTCurrent Procedural TerminologyCTcomputed tomographyCVDcardiovascular diseaseECMOextracorporeal membrane oxygenationEHRelectronic health recordHIPAAHealth Insurance Portability and Accountability ActICD-10-CMInternational Classification of Diseases, 10th Revision, Clinical ModificationMISmultisystem inflammatory syndromeMRImagnetic resonance imagingNCDRNational Cardiovascular Data RegistryPASCpostacute sequelae of SARS-CoV-2 infectionPPEprotective personal equipmentSARS-CoV-2severe acute respiratory syndrome-coronavirus-22. Methodology2.1. Writing Committee CompositionThe Task Force selected the members of this writing committee. The writing committee consisted of 15 individuals with domain expertise in cardiomyopathy, infectious disease, CVD, myocarditis, cardiovascular registries, outcomes assessment, medical informatics, health information management, and health care services research and delivery.2.2. Relationships With Industry and Other EntitiesThe Task Force made every effort to avoid actual or potential conflicts of interest because of personal, professional, or business interests or relationships of any member of the writing committee. Specifically, all members of the writing committee were required to disclose all such relationships that could be perceived as real or potential conflicts of interest in writing. The included documentation was updated when any changes occurred. Authors’ and peer reviewers’ relationships with industry and other entities pertinent to this data standards document are disclosed in Appendixes 1 and 2, respectively. In addition, for complete transparency, the disclosure information of each writing committee member—including relationships not pertinent to this document—is available in a Supplemental Appendix. The work of the writing committee was supported exclusively by the AHA and ACC without commercial support. Writing committee members volunteered their time for this effort. Meetings of the writing committee were confidential and attended only by committee members and staff.2.3. Review of Literature and Existing Data DefinitionsA substantial body of literature was reviewed for this manuscript. The primary sources of information were the “Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19,”2 NIH COVID-19 Treatment Guidelines,3 data definitions from the US Centers of Disease Control and Prevention (CDC), and previous Task Force publications. This information was augmented by multiple peer-reviewed references listed in the tables under the column “Mapping/Source of Definition.”2.4. Development of Terminology ConceptsThe writing committee aggregated, reviewed, harmonized, and extended these terms to develop a controlled, semantically interoperable, machine computable terminology set that would be usable in as many contexts as possible. As necessary, the writing committee identified contexts where individual terms required differentiation according to their proposed use (ie, research/regulatory vs. clinical care contexts).This publication was developed to serve as a common lexicon and base infrastructure by end users to augment work related to standardization and health care interoperability including, but not limited to, structural, administrative, and technical metadata development. The resulting appendixes (Appendixes 3 to 10) list the data element in the first column, followed by the clinical definition of the data element. The allowed responses (“permissible values”) for each data element in the next column are the acceptable means of recording this information. For data elements with multiple permissible values, a bulleted list of the permissible values is provided in the row listing the data element, followed by multiple rows listing each permissible value and corresponding permissible value definition, as needed. Where possible, clinical definitions (and clinical definitions of the corresponding permissible values) are repeated verbatim as previously published in reference documents.2.5. Consensus DevelopmentThe Task Force established the writing committee as described in the Task Force’s methodology paper.1 The primary responsibility of the writing committee was to aggregate existing information relevant to the care of patients with CVD from external sources, such as society guidelines and existing COVID-19 data elements from the National Cardiovascular Data Registry (NCDR)4 and AHA COVID-19 Registry.5 The work of the writing committee was accomplished via a series of virtual meetings, along with extensive email correspondence. The review work was distributed among subgroups of the writing committee based on interest and expertise in the components of the terminology set. The proceedings of the workgroups were then assembled, resulting in the vocabulary and associated descriptive text in Appendixes 3 to 10. All members reviewed and approved the final lexicon.2.6. Relation to Other StandardsThe writing committee reviewed the available published data standards, including relevant data dictionaries from registries. Relative to published data standards, the writing committee anticipates that this terminology set will facilitate the uniform adoption of these terms, where appropriate, by the clinical, clinical and translational research, regulatory, quality and outcomes, and EHR communities.2.7. Peer Review, Public Review, and Board ApprovalThe “2022 AHA/ACC Key Data Elements and Definitions for Cardiovascular and Noncardiovascular Complications of COVID-19” was reviewed by official reviewers nominated by the ACC and AHA. To increase its applicability, the document was posted on the ACC and AHA websites for a 30-day public comment period. This document was approved by the ACC Clinical Policy Approval Committee and the AHA Science Advisory and Coordinating Committee in February 2022, and the AHA Executive Committee in March 2022. The writing committee anticipates that these data standards will require review and updating in the same manner as other published guidelines, performance measures, and appropriate use criteria. The writing committee will therefore review the set of data elements on a periodic basis, starting with the anniversary of publication of the standards, to ascertain whether modifications should be considered.3. Data Elements and DefinitionsThe writing committee explicitly elected not to include patient identification, demographic, and administrative information, such as patient sex or site of service, diagnosis, and other fundamental concept terms, including data by specific medication, as defined data elements. Comprehensive EHR solutions are anticipated to collect this information as discrete data. Furthermore, a robust solution for patient identification (eg, the unique patient identifier) is a universal requirement, whether within the context of the EHR of an individual practice or the registry aggregation of information across multiple disparate inpatient and ambulatory encounters.3.1. Patient Demographics Including Age, Sex, Race, Ethnicity, and Social Determinants of HealthPatient age, sex, race, ethnicity, and social determinants of health are key elements in risk of infection and outcomes for COVID-19. Age, sex, race, and ethnicity are expected to be available in all EHR solutions and therefore have not been listed. We recognize the critical importance of social determinants of health, including race/ethnicity and sex, to COVID-19 and its outcomes and would like to emphasize that these variables should be captured. The Task Force has commissioned a separate data standards document to address social determinants of health for overall CVD, which we expect to be pertinent and complementary to this document, in addition to other documents published and being developed.63.2. COVID-19 DiagnosisAppendix 3 provides definitions for the diagnosis of COVID-19. A case of COVID-19 can be confirmed, probable, or suspected based on definitions from the CDC.7 A person with COVID-19 might be symptomatic or asymptomatic. Other categories of COVID-19 diagnosis provided include postacute sequelae of SARS-CoV-2 infection (PASC) (also termed “postacute COVID-19 syndrome” or “long COVID” in the literature); persons with COVID-19 who continue to have persistently positive molecular or antigen tests after the end of their isolation period; multisystem inflammatory syndrome (MIS), a rare postinfectious inflammatory condition; prior COVID-19; and COVID-19 reinfection. The category of COVID-19 reinfection is divided into reinfection with best evidence, moderate evidence, and poor evidence, as outlined by the CDC.8 Other data elements included in this section are date of diagnosis of acute COVID-19, whether a patient was hospitalized for COVID-19 specifically or was found to have incidental SARS-CoV-2 infection at the time of hospitalization for another cause, and dates of initial hospitalization. A category also exists for exposure to someone with COVID-19 during their infectious period, with criteria based on CDC recommendations.3.3. COVID-19 Cardiovascular ComplicationsPatients with underlying cardiovascular risk factors or established CVD are at greater risk for severe presentations of COVID-19. COVID-19 can also confer significant cardiovascular morbidity and mortality in patients with or without prior CVD. Approximately 10% to 20% of hospitalized patients can have evidence of myocardial injury in the setting of COVID-19.9 Proposed mechanisms include activation of inflammatory and thrombotic cascades, direct viral injury to myocytes or vascular endothelium, and worsening of underlying baseline atherosclerotic and structural abnormalities. Acute cardiovascular presentations are varied and include myocardial injury, myocarditis, acute coronary syndrome (ACS), heart failure, cardiogenic shock, arrhythmia, thromboembolic and cerebrovascular complications, and cardiac involvement and coronary artery ectasia in the setting of MIS in children (MIS-C). COVID-19 can trigger acute heart failure or cardiogenic shock. New-onset left ventricular systolic dysfunction is hypothesized to be related to myocarditis, endothelial and microvascular injury, myocardial stress in the setting of increased myocardial demand and reduced myocardial oxygenation in the setting of hypoxia, myocardial inflammation, and proinflammatory cytokine surge.10 New-onset right ventricular dysfunction can result from acute pulmonary embolism or strain from acute respiratory distress syndrome and elevated pulmonary artery pressures. Both atrial and ventricular arrhythmias have been noted.10 COVID-19 is associated with an increased risk of stroke, transient ischemic attack, and venous and arterial thromboembolic events.10 Appendix 4A summarizes the more common acute cardiovascular presentations and lists of standard data elements that describe these presentations.A significant proportion of patients may experience long-term complications of SARS-CoV-2 infection ≥4 weeks from the index infection, sometimes called postacute COVID-19 syndrome.11-13 Long-term cardiovascular sequelae of COVID-19 may include chest pain, palpitations, inappropriate sinus tachycardia, postural orthostatic tachycardia syndrome, atrial arrhythmia, cardiomyopathy, and thromboembolism.14-16 Possible mechanisms for long-term cardiovascular complications of COVID-19 include direct and indirect viral-mediated cellular damage, procoagulant state, the immunologic response affecting the structural integrity of the myocardium, pericardium, and conduction system, and downregulation of angiotensin-converting enzyme-2 (ACE2).17-19 Myocardial abnormalities and injury have been reported on magnetic resonance imaging (MRI), and cardiac troponin elevations have occurred in some patients >2 months after diagnosis of COVID-19.20 Myocardial fibrosis or scar associated with cardiomyopathy from viral infection can lead to arrhythmias.21 The risk for occurrence of thromboembolic complications in the postacute COVID-19 phase is possibly associated with the duration and severity of hyperinflammatory state.13 Standard data elements that describe the long-term cardiovascular complications of COVID-19 are summarized in Appendix 4B, and data elements pertaining to cardiovascular mortality from COVID-19 are summarized in Append" @default.
• W4283313755 created "2022-06-24" @default.
• W4283313755 creator A5013048872 @default.
• W4283313755 creator A5025056096 @default.
• W4283313755 creator A5026578587 @default.
• W4283313755 creator A5034416613 @default.
• W4283313755 creator A5034586607 @default.
• W4283313755 creator A5036283255 @default.
• W4283313755 creator A5039683052 @default.
• W4283313755 creator A5044992863 @default.
• W4283313755 creator A5063754844 @default.
• W4283313755 creator A5065015589 @default.
• W4283313755 creator A5066203612 @default.
• W4283313755 creator A5077468662 @default.
• W4283313755 creator A5085857819 @default.
• W4283313755 creator A5087014245 @default.
• W4283313755 creator A5091734035 @default.
• W4283313755 date "2022-07-01" @default.
• W4283313755 modified "2023-09-24" @default.
• W4283313755 title "2022 AHA/ACC Key Data Elements and Definitions for Cardiovascular and Noncardiovascular Complications of COVID-19: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards" @default.
• W4283313755 cites W1504660451 @default.
• W4283313755 cites W1693053534 @default.
• W4283313755 cites W1803784511 @default.
• W4283313755 cites W1939947548 @default.
• W4283313755 cites W1987751736 @default.
• W4283313755 cites W2014182808 @default.
• W4283313755 cites W2059472633 @default.
• W4283313755 cites W2068002666 @default.
• W4283313755 cites W2087869191 @default.
• W4283313755 cites W2113753184 @default.
• W4283313755 cites W2119340816 @default.
• W4283313755 cites W2133700167 @default.
• W4283313755 cites W2139611895 @default.
• W4283313755 cites W2150151818 @default.
• W4283313755 cites W2164186760 @default.
• W4283313755 cites W2165422796 @default.
• W4283313755 cites W2165568633 @default.
• W4283313755 cites W2170765765 @default.
• W4283313755 cites W2301666181 @default.
• W4283313755 cites W2401853487 @default.
• W4283313755 cites W2422494935 @default.
• W4283313755 cites W2571458453 @default.
• W4283313755 cites W2592096970 @default.
• W4283313755 cites W2609605008 @default.
• W4283313755 cites W2610356532 @default.
• W4283313755 cites W2620241325 @default.
• W4283313755 cites W2735046879 @default.
• W4283313755 cites W2749348258 @default.
• W4283313755 cites W2770837559 @default.
• W4283313755 cites W2792588444 @default.
• W4283313755 cites W2888543854 @default.
• W4283313755 cites W2900034165 @default.
• W4283313755 cites W2900277959 @default.
• W4283313755 cites W2903759577 @default.
• W4283313755 cites W2921285569 @default.
• W4283313755 cites W2945771063 @default.
• W4283313755 cites W2957544571 @default.
• W4283313755 cites W2973645456 @default.
• W4283313755 cites W2982303713 @default.
• W4283313755 cites W2998391591 @default.
• W4283313755 cites W3008461878 @default.
• W4283313755 cites W3008827533 @default.
• W4283313755 cites W3011483298 @default.
• W4283313755 cites W3011805169 @default.
• W4283313755 cites W3012667518 @default.
• W4283313755 cites W3012860481 @default.
• W4283313755 cites W3015438945 @default.
• W4283313755 cites W3016127017 @default.
• W4283313755 cites W3016474181 @default.
• W4283313755 cites W3016479590 @default.
• W4283313755 cites W3016959086 @default.
• W4283313755 cites W3017326650 @default.
• W4283313755 cites W3018029174 @default.
• W4283313755 cites W3019235900 @default.
• W4283313755 cites W3020167520 @default.
• W4283313755 cites W3020168167 @default.
• W4283313755 cites W3020616929 @default.
• W4283313755 cites W3020735691 @default.
• W4283313755 cites W3021992825 @default.
• W4283313755 cites W3022580747 @default.
• W4283313755 cites W3022608023 @default.
• W4283313755 cites W3023751598 @default.
• W4283313755 cites W3024782611 @default.
• W4283313755 cites W3025099228 @default.
• W4283313755 cites W3026112706 @default.
• W4283313755 cites W3027101340 @default.
• W4283313755 cites W3027918021 @default.
• W4283313755 cites W3029242200 @default.
• W4283313755 cites W3029303507 @default.
• W4283313755 cites W3032031508 @default.
• W4283313755 cites W3032981909 @default.
• W4283313755 cites W3035273565 @default.
• W4283313755 cites W3037768701 @default.
• W4283313755 cites W3037786272 @default.
• W4283313755 cites W3040801404 @default.
• W4283313755 cites W3041493976 @default.
• W4283313755 cites W3042600382 @default.
• W4283313755 cites W3043049174 @default.
• W4283313755 cites W3045277594 @default.
• W4283313755 cites W3047833576 @default.

• next